{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:31:12Z","timestamp":1793579472327,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The ability of sodium\u2013glucose co-transporter 2 (SGLT2) inhibitors to prevent atrial fibrillation (AF) has been evaluated in various studies with conflicting results. This study aimed to determine whether SGLT2 inhibitors have a protective effect against AF depending on the baseline clinical condition in which the randomized controlled trials (RCTs) were conducted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>A trial-level meta-analysis was performed including 52 RCTs (112 031 patients) comparing SGLT2 inhibitors with placebo and reporting the number of patients who developed AF in each arm. Risk ratios (RRs) for AF development with 95% confidence intervals (95% CIs) were pooled using a random-effects model. Subgroup analyses were performed by classifying RCTs according to the inclusion criteria of each trial [diabetes, chronic kidney disease, heart failure with reduced ejection fraction (HFrEF), mildly reduced EF (HFmrEF), and preserved EF (HFpEF)]. Overall, SGLT2 inhibitors prevented AF (RR = 0.86, 95% CI 0.77\u20130.96). In the subgroup analysis, the AF-preventive ability of SGLT2 inhibitors was influenced by HF, being preserved in RCTs recruiting 9141 patients with HFrEF, but not in those recruiting 12 877 subjects with HFmrEF\/HFpEF (P-value for group difference = 0.01). Meta-regression showed a reduced efficacy of SGLT2 inhibitors in preventing AF when more patients with hypertension or higher EF were enrolled (P &amp;lt; 0.01 for both).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Sodium\u2013glucose co-transporter 2 inhibitors prevent AF. Their protective effect was confirmed in the HFrEF subgroup, but not in RCTs recruiting patients with HFmrEF\/HFpEF, possibly indicating a different pathophysiology leading to AF among these conditions. However, given the limitations of a trial-level analysis, these findings are exploratory, pending confirmation from patient-level data.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf040","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T07:46:42Z","timestamp":1749023202000},"page":"441-450","source":"Crossref","is-referenced-by-count":63,"title":["Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"11","author":[{"given":"Damiano","family":"Fedele","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiovascular Division, Morgagni-Pierantoni University Hospital , Via Carlo Forlanini, 34, Forl\u00ec 47121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Casuso Alvarez","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliera-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Maida","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliera-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Vasumini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliera-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Amicone","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiovascular Division, Morgagni-Pierantoni University Hospital , Via Carlo Forlanini, 34, Forl\u00ec 47121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Canton","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiovascular Division, Morgagni-Pierantoni University Hospital , Via Carlo Forlanini, 34, Forl\u00ec 47121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Di Leo","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliera-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Basile","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliera-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Manaresi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliera-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angeli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiovascular Division, Morgagni-Pierantoni University Hospital , Via Carlo Forlanini, 34, Forl\u00ec 47121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Armillotta","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiovascular Division, Morgagni-Pierantoni University Hospital , Via Carlo Forlanini, 34, Forl\u00ec 47121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bergamaschi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiovascular Division, Morgagni-Pierantoni University Hospital , Via Carlo Forlanini, 34, Forl\u00ec 47121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4048-675X","authenticated-orcid":false,"given":"Carmine","family":"Pizzi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna , Via Zamboni, 33, Bologna 40126 ,","place":["Italy"]},{"name":"Cardiovascular Division, Morgagni-Pierantoni University Hospital , Via Carlo Forlanini, 34, Forl\u00ec 47121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"2025081219533980200_pvaf040-B1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2025081219533980200_pvaf040-B2","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"key":"2025081219533980200_pvaf040-B3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12933-024-02504-8","article-title":"SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)","volume":"23","author":"Paolisso","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2025081219533980200_pvaf040-B4","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025081219533980200_pvaf040-B5","doi-asserted-by":"crossref","first-page":"106597","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT registry","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacol Res"},{"key":"2025081219533980200_pvaf040-B6","doi-asserted-by":"crossref","first-page":"106062","DOI":"10.1016\/j.phrs.2022.106062","article-title":"Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment","volume":"176","author":"Rizzo","year":"2022","journal-title":"Pharmacol Res"},{"key":"2025081219533980200_pvaf040-B7","doi-asserted-by":"crossref","first-page":"110766","DOI":"10.1016\/j.diabres.2023.110766","article-title":"Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: insight from SGLT2-I AMI PROTECT registry","volume":"202","author":"Paolisso","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2025081219533980200_pvaf040-B8","doi-asserted-by":"crossref","first-page":"e022222","DOI":"10.1161\/JAHA.121.022222","article-title":"Sodium-glucose Co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Pandey","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025081219533980200_pvaf040-B9","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/FJC.0000000000001183","article-title":"Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials","volume":"79","author":"Zheng","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025081219533980200_pvaf040-B10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-023-01860-1","article-title":"Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review","volume":"22","author":"Ouyang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2025081219533980200_pvaf040-B11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","article-title":"Sodium\u2013glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis","volume":"31","author":"Zhang","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025081219533980200_pvaf040-B12","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025081219533980200_pvaf040-B13","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2025081219533980200_pvaf040-B14","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12933-023-02019-8","article-title":"SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study","volume":"22","author":"Li","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2025081219533980200_pvaf040-B15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00395-023-01022-0","article-title":"Acute antiarrhythmic effects of SGLT2 inhibitors\u2013dapagliflozin lowers the excitability of atrial cardiomyocytes","volume":"119","author":"Paasche","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"2025081219533980200_pvaf040-B16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12933-023-01913-5","article-title":"Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance","volume":"22","author":"Shu","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2025081219533980200_pvaf040-B17","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/HYPERTENSIONAHA.122.19459","article-title":"Atrial fibrillation detection and management in hypertension","volume":"80","author":"Gawa\u0142ko","year":"2023","journal-title":"Hypertension"},{"key":"2025081219533980200_pvaf040-B18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/CIRCULATIONAHA.122.057444","article-title":"Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction","volume":"146","author":"Reddy","year":"2022","journal-title":"Circulation"},{"key":"2025081219533980200_pvaf040-B19","doi-asserted-by":"crossref","first-page":"ii52","DOI":"10.1093\/europace\/euaa346","article-title":"Risk factor management and atrial fibrillation","volume":"23","author":"Hendriks","year":"2021","journal-title":"EP Europace"},{"key":"2025081219533980200_pvaf040-B20","doi-asserted-by":"crossref","first-page":"106591","DOI":"10.1016\/j.phrs.2022.106591","article-title":"Atrial fibrillation: epigenetic aspects and role of sodium-glucose cotransporter 2 inhibitors","volume":"188","author":"Donniacuo","year":"2023","journal-title":"Pharmacol Res"},{"key":"2025081219533980200_pvaf040-B21","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jacc.2022.08.718","article-title":"Atrial fibrillation and dapagliflozin efficacy in patients with preserved or mildly reduced ejection fraction","volume":"80","author":"Butt","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025081219533980200_pvaf040-B22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/CIRCULATIONAHA.120.051992","article-title":"Randomized, controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus","volume":"143","author":"Shim","year":"2021","journal-title":"Circulation"},{"key":"2025081219533980200_pvaf040-B23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4250\/jcvi.2021.0159","article-title":"Effects of Sodium\/Glucose Cotransporter 2 (SGLT2) inhibitors on cardiac imaging parameters: a systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Wee","year":"2022","journal-title":"J Cardiovasc Imaging"},{"key":"2025081219533980200_pvaf040-B24","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"2025081219533980200_pvaf040-B25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure","volume":"14","author":"Santos-Gallego","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025081219533980200_pvaf040-B26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ehjcvp\/pvaf003","article-title":"Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography\u2014a subanalysis of the EMPAG-HF trial","volume":"11","author":"Bogoviku","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025081219533980200_pvaf040-B27","doi-asserted-by":"crossref","first-page":"e016424","DOI":"10.1161\/CIRCIMAGING.123.016424","article-title":"Left atrial roof enlargement is a distinct feature of heart failure with preserved ejection fraction","volume":"17","author":"Backhaus","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"2025081219533980200_pvaf040-B28","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s10554-024-03145-4","article-title":"CMR-based cardiac phenotyping in different forms of heart failure","volume":"40","author":"Lange","year":"2024","journal-title":"Int J Cardiovasc Imaging"},{"key":"2025081219533980200_pvaf040-B29","doi-asserted-by":"crossref","first-page":"e031269","DOI":"10.1161\/JAHA.123.031269","article-title":"Impact of sodium-glucose cotransporter 2 inhibitor on recurrence after catheter ablation for atrial fibrillation in patients with diabetes: a propensity-score matching study and meta-analysis","volume":"12","author":"Zhao","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2025081219533980200_pvaf040-B30","doi-asserted-by":"crossref","first-page":"1012220","DOI":"10.3389\/fcvm.2022.1012220","article-title":"In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: insights from the SGLT2-I AMI PROTECT study","volume":"9","author":"Cesaro","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025081219533980200_pvaf040-B31","doi-asserted-by":"crossref","first-page":"e030552","DOI":"10.1161\/JAHA.123.030552","article-title":"Differing efficacy of dapagliflozin versus empagliflozin on the risk of incident atrial fibrillation in patients with type 2 diabetes: a real-world observation using a nationwide, population-based cohort","volume":"13","author":"Lim","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2025081219533980200_pvaf040-B32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","article-title":"SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials","volume":"19","author":"Li","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2025081219533980200_pvaf040-B33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2025081219533980200_pvaf040-B34","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/eurjpc\/zwad372","article-title":"SGLT2 inhibitors: a therapy for everybody but not for anything?","volume":"31","author":"Villaschi","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025081219533980200_pvaf040-B35","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacep.2022.08.004","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitors on outcomes after catheter ablation for atrial fibrillation","volume":"8","author":"Kishima","year":"2022","journal-title":"JACC Clin Electrophysiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf040\/63435219\/pvaf040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/5\/441\/63435219\/pvaf040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/5\/441\/63435219\/pvaf040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T23:53:52Z","timestamp":1755042832000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/5\/441\/8156661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,6,4]]},"published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf040","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,6,4]]}}}